DNA Sequence Analysis of SLC26A5, Encoding Prestin, in a Patient-Control Cohort: Identification of Fourteen Novel DNA Sequence Variations by Minor, Jacob S. et al.
DNA Sequence Analysis of SLC26A5, Encoding Prestin, in
a Patient-Control Cohort: Identification of Fourteen
Novel DNA Sequence Variations
Jacob S. Minor
1¤, Hsiao-Yuan Tang
1, Fred A. Pereira
1,2, Raye Lynn Alford
1*
1Bobby R. Alford Department of Otolaryngology – Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, United States of America, 2Huffington Center on
Aging and Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas, United States of America
Abstract
Background: Prestin, encoded by the gene SLC26A5, is a transmembrane protein of the cochlear outer hair cell (OHC).
Prestin is required for the somatic electromotile activity of OHCs, which is absent in OHCs and causes severe hearing
impairment in mice lacking prestin. In humans, the role of sequence variations in SLC26A5 in hearing loss is less clear.
Although prestin is expected to be required for functional human OHCs, the clinical significance of reported putative
mutant alleles in humans is uncertain.
Methodology/Principal Findings: To explore the hypothesis that SLC26A5 may act as a modifier gene, affecting the severity
of hearing loss caused by an independent etiology, a patient-control cohort was screened for DNA sequence variations in
SLC26A5 using sequencing and allele specific methods. Patients in this study carried known pathogenic or controversial
sequence variations in GJB2, encoding Connexin 26, or confirmed or suspected sequence variations in SLC26A5; controls
included four ethnic populations. Twenty-three different DNA sequence variations in SLC26A5, 14 of which are novel, were
observed: 4 novel sequence variations were found exclusively among patients; 7 novel sequence variations were found
exclusively among controls; and, 12 sequence variations, 3 of which are novel, were found in both patients and controls.
Twenty-one of the 23 DNA sequence variations were located in non-coding regions of SLC26A5. Two coding sequence
variations, both novel, were observed only in patients and predict a silent change, p.S434S, and an amino acid substitution,
p.I663V. In silico analysis of the p.I663V amino acid variation suggested this variant might be benign. Using Fisher’s exact
test, no statistically significant difference was observed between patients and controls in the frequency of the identified
DNA sequence variations. Haplotype analysis using HaploView 4.0 software revealed the same predominant haplotype in
patients and controls and derived haplotype blocks in the patient-control cohort similar to those generated from the
International HapMap Project.
Conclusions/Significance: Although these data fail to support a hypothesis that SLC26A5 acts as a modifier gene of GJB2-
related hearing loss, the sample size is small and investigation of a larger population might be more informative. The 14
novel DNA sequence variations in SLC26A5 reported here will serve as useful research tools for future studies of prestin.
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Introduction
The human ear is capable of perceiving sounds from 20–
20,000 Hz and can distinguish a difference of as little as 0.2–0.5%
[1,2]. Such sensitivity and precision, seen also among other
mammals, derives from a complex interaction of cochlear hair cells
and the tectorial membrane (TM) within the organ of Corti.
Stereocilia,which sit atop the outer hair cells (OHCs), embed within
the TM and are deflected with the passage of sound pressure waves,
triggering mechanotransducer ion channels to open and close,
allowing the cell to depolarize and hyperpolarize, respectively.
These changes in OHC membrane potential are converted into
mechanical forces, causing the cell to rapidly lengthen and shorten,
and in turn, move the basilar membrane, to result in a hundred-fold
amplification of sound and a vastly improved ability to discriminate
frequencies. An essential protein responsible for the electromechan-
ical conversion in the OHC is prestin [3,4].
The SLC26A5 gene encodes prestin. Most genes of the SLC26
family encode anion transporters, however, mammalian prestin
has only been demonstrated to be an incomplete anion transporter
[4–6]. Further, prestin is more highly conserved among mamma-
lian species than any other protein in its family: demonstrating
95% amino acid identity between mouse and human, compared to
an average of 86% for the group [7]. Prestin also appears to have a
role beyond the OHC since SLC26A5 transcripts are found in
heart, spleen, brain, and testis [8].
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loss [9]. Mutational analyses by several groups have identified
many residues that are essential for and/or modulate prestin
function [10–13]. However, linkage studies of hearing impaired
families have failed so far to map SLC26A5 as a locus associated
with human hearing loss [14].
Only three sequence variations presumed to affect the coding
sequence of SLC26A5 in humans have been reported to date. In
2003, Liu et al. reported a DNA sequence variation, IVS2-2A.G,
in a population that included two deaf probands homozygous for
the variant. The IVS2-2A.G variant was predicted to disrupt the
exon 3 splice acceptor site [15]. However, in 2005, we reported a
carrier frequency among Caucasian controls of 4.1% for this
variant, precluding its involvement in hereditary hearing loss [16].
In addition, the Celera database includes a missense variation,
p.I67V, however, nothing is known about the hearing status of the
individual carrying this variant, prohibiting audiometric assess-
ment of its potential pathogenicity [17]. Recently, in 2007, Toth et
al. reported a p.R150Q missense variation in one hearing
impaired patient and his normal hearing father, suggesting the
p.R150Q variant is not sufficient to cause hearing loss [18].
At the time this study was undertaken, the p.I67V variant was the
only reported amino acid substitution in prestin [17] and only 447
non-coding SNPs were reported in the 49.24 kilobase genomic
region of human SLC26A5 [19]. Due to the paucity of known
sequence variations in the human SLC26A5 gene, evaluation of a
patient-control cohort was undertaken to seek additional sequence
variations in SLC26A5 and explore the hypothesis that variations in
prestin might modify the degree of hearing loss caused by an
independent etiology. Fourteen novel DNA sequence variations in
SLC26A5 were identified, however, no evidence supporting a
hypothesis that SLC26A5might act as a modifier gene was obtained.
Results
Analysis of the SLC26A5 DNA sequence
Genomic DNA isolated from peripheral blood lymphocytes or
cultured lymphoblastoid cell lines of a patient-control cohort was
evaluated for 11 previously reported DNA sequence variations in
SLC26A5 using DNA sequencing and allele specific methods. In the
course of evaluating these 11 previously known sequence variations,
14 novel DNA sequence variations were observed. Table 1 shows
the genomic DNA position, nucleotide sequence variation,
polymorphism identification number, and location in the SLC26A5
gene for all 25 SLC26A5 sequence variations evaluated.
SLC26A5 DNA sequence variations observed among
patients
Sixteen different DNA sequence variations, 7 of which are
novel, were identified in the SLC26A5 gene in hearing impaired
patients. Sequence variations included 15 single nucleotide
substitutions, 6 of which are novel, and 1 novel small (tri-
nucleotide) deletion. Fourteen of the DNA sequence variations
identified among patients, 13 single nucleotide substitutions and
the 1 small deletion, were found in introns, while 2 single
nucleotide substitutions were found in the coding region of
SLC26A5 including g.56167A.G which predicts a synonymous
change p.S434S and g.69743A.G which predicts the amino acid
substitution p.I663V (Table 1, Table 2).
The patient carrying the heterozygous p.S434S variation in
SLC26A5 is also homozygous for the SLC26A5 variants
g.33167T.C (dbSNP rs7779997), g.56471G.A (dbSNP
rs4285410), g.67439T.C (dbSNP rs12705120) and
g.69036T.C (dbSNP rs10273883) (data not shown).
The patient carrying the heterozygous p.I663V variation in
SLC26A5 is also heterozygous for the SLC26A5 variants
g.33167T.C (dbSNP rs7779997), g.57137T.C (dbSNP
rs62482415), and g.69917_69919delTCT (dbSNP rs66928926),
and homozygous for the SLC26A5 variants g.56471G.A (dbSNP
rs4285410), g.67439T.C (dbSNP rs12705120) and g.69036T.C
(dbSNP rs10273883) (data not shown).
DNA sequence variations were not found in patients in the
coding or near coding regions of SLC26A5 exons 4, 7, 8, 9, 17, 20,
or 21.
SLC26A5 DNA sequence variations observed among
controls
Nineteen different DNA sequence variations, 10 of which are
novel, were identified in the SLC26A5 gene in controls. Sequence
variations included 17 single nucleotide substitutions, 8 of which
are novel, and 2 novel small deletions (1 tri-nucleotide deletion
and 1 penta-nucleotide deletion). All DNA sequence variations
identified among controls were found in introns (Table 1, Table 2).
Due to the lack of DNA sequence variations in the coding or near
coding regions of SLC26A5 exons 4, 7, 8, 9, 17, 20, and 21 among
patients, these exons were not analyzed in controls.
Table 1. DNA sequence variations in SLC26A5.
DNA sequence variation SNP ID Location
g.24586A.G (IVS2-2A.G) IVS2
g.33167T.C rs7779997 IVS5
g.33190T.G rs72655379 IVS5
g.34821C.T rs56305143* IVS6
g.53884C.T rs62482417 IVS10
g.55275A.G rs72655388 IVS11
g.56167A.G (p.S434S) rs72655380 Exon 12
g.56381C.A rs72655389 IVS12
g.56388G.C rs4604353 IVS12
g.56417G.A rs72655390 IVS12
g.56471G.A rs4285410 IVS12
g.57105G.A rs72655391 IVS12
g.57132C.T rs56373660 IVS12
g.57137T.C rs62482415 IVS12
g.57164G.T rs72655392 IVS12
g.57365A.G rs72655381 IVS13
g.66012C.T rs72655395 IVS14
g.67439T.C rs12705120 IVS16
g.69036T.C rs10273883 IVS18
g.69743A.G (p.I663V) rs72655382 Exon 19
g.69904T.C rs72655393 IVS19
g.69917_69919delTCT rs66928926 IVS19
g.70029G.A rs62482412 IVS19
g.70078_70082delATATA rs72655394 IVS19
g.70118A.G rs72655378 IVS19
Entrez database (http://www.ncbi.nlm.nih.gov) reference sequence genomic
DNA positions and nucleotide (splice site/protein) variations, dbSNP SNP ID
numbers [19], and genetic locations within SLC26A5 are shown. *formerly
hCG1811409, Celera database [17]. IVS=intervening sequence (intron). Novel
variants are shown in bold type.
doi:10.1371/journal.pone.0005762.t001
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Heterozygosity (H) for each of the DNA sequence variations
evaluated in patients and controls is shown in Table 3. Allelic
variation was observed for all but 2 of the 11 previously known
sequence variations in SLC26A5: g.56471G.A; and, g.67439T.C
(Table 2, Table 3). No subject was found to be homozygous for
any coding region sequence variation in SLC26A5.
Analysis of sequence variants in IVS2-2A.G
heterozygotes
Eight subjects (4 patients and 4 controls) included in this study
were heterozygous for the previously reported g.24586A.G
(IVS2-2A.G) nucleotide substitution in SLC26A5 [15]. These 8
subjects were previously described [16] and were included here for
further evaluation of the coding and near coding DNA sequence of
SLC26A5. In addition to carrying the IVS2-2A.G variant, these
subjects also carried additional sequence variations in SLC26A5 as
described in Table 4.
In silico analysis of amino acid sequence variations
The p.I663V amino acid sequence variation observed in this
study, and the previously reported p.I67V [17] and p.R150Q [18]
amino acid sequence variations were evaluated using the PolyPhen
(http://genetics.bwh.harvard.edu/pph/) [20] and SIFT (http://
blocks.fhcrc.org/sift/SIFT.html) [21] sequence analysis algorithms
and by multiple sequence alignment of prestin orthologs using the
HomoloGene application available through the National Center
for Biotechnology Information (NCBI) web site (http://ww.ncbi.
nlm.nih.gov).
PolyPhen analysis predicts the p.I67V and p.I663V variants
would be benign and the p.R150Q variant may be possibly
damaging. SIFT analysis predicts all three variants, p.I67V,
p.R150Q, and p.I663V would be tolerated (data not shown). The
degree of conservation of amino acids numbered p.I67, p.R150
and p.I663 in the human prestin amino acid sequence is shown in
Table 5. All three amino acids are conserved in dog, cow, mouse
and rat. Conservation of these amino acids in other species varies
as shown (Table 5).
Haplotype analysis of SLC26A5
To determine whether specific SLC26A5 alleles might be
associated with hearing loss, and therefore overrepresented in
the patient group, haplotypes and haplotype blocks within
SLC26A5 were derived using HaploView 4.0 software (http://
Table 2. Reference sequence allele frequencies for variations in SLC26A5.
DNA sequence variation Patients Controls P value
(n=56)
African
American
(n=52)
Asian
(n=52)
Caucasian
(n=56)
Hispanic
(n=52)
Combined
(n=212)
g.24586A.G (IVS2-2A.G) 0.93 1.00 1.00 0.95 0.98 0.98 0.06
g.33167T.C 0.70 0.27 0.63 0.73 0.75 0.60 0.22
g.33190T.G 0.98 1.00 1.00 1.00 1.00 1.00 0.21
g.34821C.T 0.89 0.98 0.90 0.91 0.92 0.93 0.40
g.53884C.T 0.98 1.00 1.00 0.98 0.98 0.99 0.51
g.55275A.G 0.98 0.77 1.00 1.00 0.96 0.93 0.21
g.56167A.G (p.S434S) 0.98 1.00 1.00 1.00 1.00 1.00 0.21
g.56381C.A 1.00 0.98 1.00 1.00 1.00 1.00 1.00
g.56388G.C 0.98 0.90 1.00 1.00 1.00 0.98 1.00
g.56417G.A 1.00 1.00 1.00 1.00 0.98 1.00 1.00
g.56471G.A 0.00 0.00 0.00 0.00 0.00 0.00 1.00
g.57105G.A 1.00 0.94 1.00 1.00 1.00 0.99 1.00
g.57132C.T 0.89 0.98 0.90 0.91 0.92 0.93 0.40
g.57137T.C 0.86 0.92 0.98 0.80 0.90 0.90 0.34
g.57164G.T 1.00 1.00 1.00 1.00 0.98 1.00 1.00
g.57365A.G 0.98 1.00 1.00 1.00 1.00 1.00 0.21
g.66012C.T 0.98 0.88 1.00 1.00 1.00 0.97 1.00
g.67439T.C 0.00 0.00 0.00 0.00 0.00 0.00 1.00
g.69036T.C 0.02 0.15 0.00 0.00 0.00 0.04 0.69
g.69743A.G (p.I663V) 0.98 1.00 1.00 1.00 1.00 1.00 0.21
g.69904T.C 1.00 0.92 1.00 1.00 1.00 0.98 0.58
g.69917_69919delTCT 0.96 0.69 1.00 0.98 1.00 0.92 0.38
g.70029G.A 0.88 0.98 0.96 0.80 0.81 0.89 0.82
g.70078_70082delATATA 1.00 0.98 1.00 1.00 1.00 1.00 1.00
g.70118A.G 1.00 1.00 1.00 0.98 1.00 1.00 1.00
Allele frequencies of reference sequence nucleotides are provided for each DNA sequence variant. n=the number of chromosomes studied. P values are calculated by
comparing patients to the combined control group. Novel variants are shown in bold type.
doi:10.1371/journal.pone.0005762.t002
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lotype blocks were derived for the patient group, the control group
and the combined patient-control cohort. Haplotype blocks
derived for the patient-control cohort were compared to haplotype
blocks derived for the International HapMap Project database
markers (http://www.hapmap.org) [23].
The predominant SLC26A5 haplotype observed in patients was
also the predominant haplotype observed among controls.
Although some differences are observed in the boundaries of
haplotype blocks, the overall haplotype block pattern for SLC26A5
appears similar for each of the four groups analyzed (Figure 1).
Discussion
Twenty-three different DNA sequence variations in SLC26A5,
14 of which are novel, were observed. Allelic variation for two
previously reported DNA sequence variations in SLC26A5 was not
observed in this study (Table 1, Table 2, Table 3). Twelve of the
Table 3. Heterozygosity of sequence variations in SLC26A5.
DNA sequence variation Patients Controls
(n=28)
African American
(n=26)
Asian
(n=26)
Caucasian
(n=28)
Hispanic
(n=26)
Combined
(n=106)
g.24586A.G (IVS2-2A.G) 0.14 0.00 0.00 0.11 0.04 0.04
g.33167T.C 0.32 0.38 0.35 0.32 0.35 0.35
g.33190T.G 0.04 0.00 0.00 0.00 0.00 0.00
g.34821C.T 0.14 0.04 0.12 0.18 0.15 0.12
g.53884C.T 0.04 0.00 0.00 0.04 0.04 0.02
g.55275A.G 0.04 0.38 0.00 0.00 0.08 0.11
g.56167A.G (p.S434S) 0.04 0.00 0.00 0.00 0.00 0.00
g.56381C.A 0.00 0.04 0.00 0.00 0.00 0.01
g.56388G.C 0.04 0.19 0.00 0.00 0.00 0.05
g.56417G.A 0.00 0.00 0.00 0.00 0.04 0.01
g.56471G.A 0.00 0.00 0.00 0.00 0.00 0.00
g.57105G.A 0.00 0.12 0.00 0.00 0.00 0.03
g.57132C.T 0.14 0.04 0.12 0.18 0.15 0.12
g.57137T.C 0.21 0.15 0.04 0.32 0.19 0.18
g.57164G.T 0.00 0.00 0.00 0.00 0.04 0.01
g.57365A.G 0.04 0.00 0.00 0.00 0.00 0.00
g.66012C.T 0.04 0.23 0.00 0.00 0.00 0.06
g.67439T.C 0.00 0.00 0.00 0.00 0.00 0.00
g.69036T.C 0.04 0.31 0.00 0.00 0.00 0.08
g.69743A.G (p.I663V) 0.04 0.00 0.00 0.00 0.00 0.00
g.69904T.C 0.00 0.15 0.00 0.00 0.00 0.04
g.69917_69919delTCT 0.07 0.38 0.00 0.04 0.00 0.10
g.70029G.A 0.18 0.04 0.08 0.32 0.23 0.17
g.70078_70082delATATA 0.00 0.04 0.00 0.00 0.00 0.01
g.70118A.G 0.00 0.00 0.00 0.04 0.00 0.01
Heterozygosity is provided for each DNA sequence variation. n=the number of individuals studied. Novel variants are shown in bold type.
doi:10.1371/journal.pone.0005762.t003
Table 4. Other DNA sequence variations observed in SLC26A5 IVS2-2A.G heterozygotes.
DNA sequence variation Patients Controls
g.24586A.G ( IVS2-2A.G) Het Het Het Het Het Het Het Het
g.33167T.C Het Hom Var Hom Var Het Hom Ref Het Hom Var Hom Var
g.57137T.C Het Het Hom Var Het Hom Ref Het Het Hom Var
g.70029G.A Het Het Hom Var Het Hom Ref Het Het Hom Var
Additional sequence variations observed in the patient and control samples heterozygous for the SLC26A5 IVS2-2A.G variant are shown. All eight subjects were also
homozygous for the variant alleles at g.56471G.A, g.67439T.C, and g.69036T.C (not shown). Het=heterozygous; Hom=homozygous; Ref=reference sequence
allele; Var=variant allele.
doi:10.1371/journal.pone.0005762.t004
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tions (SNPs) while 2 are small deletions. Four novel DNA sequence
variations were found exclusively among patients. Seven novel
DNA sequence variations were found exclusively among controls.
Three novel DNA sequence variations, plus an additional 9
previously reported sequence variations, were found in both
patients and controls.
Twenty-one of the 23 DNA sequence variations identified in
this study were found in non-coding regions of SLC26A5. Two
DNA sequence variations, both of which are novel, were found in
coding regions of SLC26A5. Both coding region changes, a
nucleotide substitution predicted not to alter the amino acid
sequence of prestin, p.S434S, and a nucleotide substitution
predicted to result in a missense variation, p.I663V, were found
only in patients. No statistically significant difference was observed
between patients and controls in the frequency of any DNA
sequence variation identified in this study.
Prior to this report, only three other DNA sequence variations
expected to affect the coding sequence of human SLC26A5 were
known: splice site variant IVS2-2A.G upstream of the ATG start
Table 5. Multiple sequence alignment for observed and previously reported [17,18] amino acid sequence variations in prestin.
Species (gene/protein) Protein Reference Sequence aa 67 aa 150 aa 663
H. sapiens (SLC26A5) NP_945350.1 I R I
C. lupus (SLC26A5) XP_540393.2 I R I
B. taurus (SLC26A5) XP_616468.2 I R I
M. musculus (Slc26a5) NP_109652.3 I R I
R. norvegicus (Slc26a5) NP_110467.1 I R I
G. gallus (SLC26A5) XP_415959.2 I R V
D. rerio (slc26a5) NP_958881.1 I R V
D. melanogaster (Prestin) NP_649024.1 I T L
A. gambiae (AgaP_AGAP010389) XP_559067.1 I N V
C. elegans (sulp-7) NP_001033571.1 I R I
C. elegans (sulp-8) NP_505493.1 I R V
C. elegans (sulp-4) NP_505989.1 I K I
C. elegans (sulp-5) NP_505990.2 I R V
C. elegans (sulp-3) NP_509424.2 I K V
A. thaliana (SULTR4;1) NP_196859.1 C - L
A. thaliana (SULTR4;2 ) NP_187858.1 C - L
O. sativa (Os09g0240500) NP_001062644.1 C - L
Amino acid alignments of prestin orthologs from various species are shown using H. sapiens as the anchor sequence. Amino acid (aa) positions 67, 150, and 663
indicated in the top row of columns 3–5 refer to the amino acid positions in the human prestin amino acid sequence. Reference sequences used are derived from the
NCBI protein database and aligned using the NCBI HomoloGene multiple sequence alignment tool (http://www.ncbi.nlm.nih.gov).
doi:10.1371/journal.pone.0005762.t005
Figure 1. Haplotype analysis of patients and controls compared to International HapMap Project database markers. Haplotype
blocks as determined by HaploView 4.0 are shown as shaded bars and compared for patients, controls, patients and controls combined (Combined),
and the International HapMap Project database markers (HapMap). The location of markers within the SLC26A5 gene is shown at the top of the figure.
DNA sequence variations are shown above the haplotype blocks. Note: The only marker observed in this study that is included in the International
HapMap Project database is rs7779997 in IVS5. The genomic SLC26A5 nucleotides spanned by the haplotype blocks derived from the International
HapMap Project database markers are shown at the bottom of the figure. Abbreviations and symbols used: IVS, intervening sequence (intron);
*formerly hCG1811409, Celera database [17]; #, C allele noted is variant allele, not reference sequence allele; 2, Variant allele not detected; +,
Reference allele not detected; 1, 2, 3, 4, represent haplotype block designations derived from and assigned by HaploView 4.0 software analysis of the
International HapMap Project database markers. The reference sequence (undeleted) allele of variant rs66928926 (g.69917_69919delTCT) is
designated as ‘‘T’’ and of variant rs72655394 (g.70078_70082delATATA) is designated as ‘‘A.’’ Novel variants are shown in bold type.
doi:10.1371/journal.pone.0005762.g001
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p.R150Q [18]. Although additional coding sequence variants will
reasonably be expected to be found in future studies it is striking
that such a small number of coding sequence variants have been
described so far in this rather large gene whose longest isoform
produces a protein containing 744 amino acids. This observation
suggests a remarkably high degree of conservation of this SLC26
family protein in humans.
The IVS2-2A.G variant reported in 2003 by Liu et al. was
found in that study in hearing impaired patients, including two
probands homozygous for the variant, and in controls [15]. This
sequence variation was suspected of disrupting the splicing of
SLC26A5 exon 3, which contains the prestin ATG start codon,
thereby disrupting prestin protein production. However, the
difference in allele frequency between patients and controls in
the study was not statistically significant if the consanguineous
proband was excluded from the analysis, p=0.056 [15]. In an
effort to further analyze the IVS2-2A.G transition, we reported
in 2005 a patient-control cohort that demonstrated a carrier
frequency for the IVS2-2A.G transition among deaf Caucasians
of 5.6% and a carrier frequency among control Caucasians of
4.1%, p=0.66 [16]. In addition, we identified five possible
alternate splice sites in intron 2 which could potentially
compensate for the IVS2-2A.G variation [16]. If the IVS2-
2A.G variant was in fact associated with hearing loss in humans,
based on the carrier rate of 4.1% observed among Caucasians, the
contribution to hereditary hearing loss in humans of this SLC26A5
variant could reasonably be expected to be greater than that of
mutations in GJB2, encoding Connexin 26, which have a carrier
rate among Caucasians of approximately 3% [24]. Based on these
observations, it is curious that SLC26A5 has not been mapped by
linkage studies as a DFN locus [14]. Further investigation is
needed into what role, if any, the IVS2-2A.G variation in
SLC26A5 might have in human hearing loss [16].
The p.I67V amino acid substitution was reported in the Celera
database [17]. Because nothing is known about the health or
hearing status of the individual(s) carrying this variant, its potential
pathogenicity is unknown. The PolyPhen protein analysis tool
predicts the p.I67V variation to be benign and the SIFT protein
analysis tool predicts the p.I67V variation to be tolerated (data not
shown). Multiple sequence alignment demonstrates a high degree
of conservation of this amino acid (Table 5). In this study, the
p.I67V variant was not observed among patients and was not
sought among controls. Further investigation of the p.I67V amino
acid variant is needed to assess what impact, if any, it might have
on prestin production, trafficking and/or function.
The previously reported p.R150Q amino acid substitution was
observed in a hearing impaired patient and his normal-hearing
father, suggesting that this amino acid substitution is not sufficient
to cause hearing loss [18]. PolyPhen analysis suggests the p.R150Q
variant may be possibly damaging, however, SIFT analysis
predicts this variation would be tolerated (data not shown).
Multiple sequence alignment demonstrates a fairly high degree of
conservation of this amino acid (Table 5). In this study, the
p.R150Q variant was not observed among patients and was not
sought among controls. Further analysis of the p.R150Q amino
acid variant is needed to assess what role, if any, it might have in
hearing loss.
The novel DNA sequence variation g.56167A.G which is
predicted to represent a synonymous p.S434S variation was found
in this study in a patient with bilateral, progressive, mild to
moderate sensorineural hearing loss who is also homozygous for
the controversial p.V37I variation in GJB2 [25]. This patient also
demonstrates mildly prominent vestibular aqueducts bilaterally, a
finding not consistent with a GJB2-based etiology and suggestive of
a more complex etiology for the hearing loss. Because this
sequence variation does not result in an amino acid substitution, it
would not be predicted to be pathogenic unless it disrupts splicing
of the SLC26A5 transcript. Since the p.S434S variation does not
predict an amino acid substitution, analysis by PolyPhen and SIFT
is not warranted. Further analysis of the g.56167A.G DNA
sequence variant is required to assess what impact, if any, it might
have on prestin production, trafficking and/or function.
The novel DNA sequence variation g. 69743A.G which is
predicted to result in a p.I663V amino acid substitution was
observed in this study in a patient with bilateral, profound
sensorineural hearing loss who is also homozygous for the
pathogenic c.35delG mutation in GJB2. The detection of a
homozygous c.35delG mutation in GJB2 in this patient provides a
clear etiology for this patient’s hearing loss without the need to
invoke additional contributing factors. Further, PolyPhen analysis
predicts the p.I663V variant would be benign and SIFT analysis
predicts p.I663V would be tolerated by the prestin protein (data
not shown). Multiple sequence alignment demonstrates some
degree of conservation of this amino acid, especially among
mammals, however, in some other species the isoleucine at this
position is replaced by a valine (Table 5). Further analysis of the
p.I663V amino acid variant is needed to assess what impact, if
any, this variant might have on prestin production, trafficking
and/or function.
Haplotype analysis of SLC26A5 was conducted to determine
whether novel or unusual haplotypes or haplotype blocks occurred
in the patient population that might suggest an association of
particular SLC26A5 alleles with hearing loss. Haplotype analysis
using HaploView 4.0 software [22] revealed haplotypes in patients
similar to those in controls and haplotype blocks in the patient-
control cohort similar to those generated from International
HapMap Project data [23]. Although slight differences in the
boundaries of the haplotype blocks are observed between the
patient, control, combined patient-control cohort, and Interna-
tional HapMap Project database marker groups, the overall
haplotype block pattern is similar between the four groups. As
such, these data fail to detect any major haplotypes or haplotype
block structures unique to patients. It is likely that the slight
differences in haplotype blocks observed are related to the small
population size utilized in this study. Evaluation of additional
patient and control populations in future studies may reveal
haplotype blocks more similar to those derived using markers from
the International HapMap Project database [23].
In summary, 12 novel SNPs and 2 novel small deletions are
reported in the human SLC26A5 gene encoding prestin. Although
no significant difference in the frequency of any DNA sequence
variation was found between patients and controls and no data
was found to support the hypothesis that SLC26A5 may act as a
modifier of GJB2-based hearing loss in this population of hearing
impaired patients, the population included in this study was small.
Future studies on larger patient and control populations may yield
more informative results. Identification of the 14 novel DNA
sequence variations described here should facilitate future studies
of SLC26A5 and the role of the encoded prestin protein in human
hearing sensitivity and hearing loss.
Materials and Methods
Ethics Statement
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Institutional Review Board (IRB). Written informed consent was
obtained from all subjects, as directed by the IRB.
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Patients and controls were identified as previously described and
reported [16,25]. Of the 28 patients included in this study: 22
carry DNA sequence variations in GJB2, encoding Connexin 26,
of known, controversial, or uncertain pathogenicity [25]; 4 carry
the previously reported SLC26A5 IVS2-2A.G variant [16]; and, 2
were suspected of carrying another non-coding sequence variation
in intron 2 of SLC26A5 (data not shown). The ethnicity of patients
is not always known. The 22 patients carrying known or potential
mutations in GJB2 were included in this study specifically to test
the hypothesis that SLC26A5 might act as a modifier gene of GJB2-
based hearing loss.
Controls were obtained from the Baylor Polymorphism
Resource (http://www.bcm.edu/blg/showned.cfm?01-106). The
control population includes 4 different ethnic groups. Ethnicity of
individuals in the control population was self-identified. Four
controls previously reported to carry the SLC26A5 IVS2-2A.G
variant [16] were included in this study specifically to search for
additional SLC26A5 variants in these individuals.
Reference sequences
Entrez nucleotide database (http://www.ncbi.nlm.nih.gov/)
sequence NT_079596.2 was used as the reference sequence for
SLC26A5. Numbering of nucleotides in SLC26A5 begins with
position 1 of the Entrez sequence as position g.1.
Entrez protein database (http://www.ncbi.nlm.nih.gov/) se-
quence NP_945350.1 was used as the reference sequence for
prestin. Numbering of amino acids in prestin begins with position
1 of the Entrez sequence as position p.1.
DNA sequence variation nomenclature
DNA and protein sequence variations are named according to
standard nomenclature recommendations [26,27].
Specimen collection
As previously described [16,25], blood samples were collected
from all subjects by peripheral venipuncture in lavender top
(EDTA) and/or yellow top (ACD) tubes. For some patients and all
control specimens, lymphoblastoid cell lines were established from
blood samples collected in yellow top (ACD) tubes by standard
Epstein Barr virus mediated transformation.
DNA isolation
As previously described [16,25], genomic DNA was isolated
from blood samples collected in lavender top (EDTA) tubes using
the PUREGENEH DNA Purification Kit for whole blood and
bone marrow and from cultured cells using the PUREGENEH
DNA Purification Kit for cells, tissue, body fluids, and Gram-
negative bacteria (Gentra Systems, Inc., Minneapolis, Minnesota,
USA) according to the manufacturer’s specifications.
DNA sequence analysis
Of patients. The coding and near coding regions of all exons
in all isoforms of SLC26A5 were sequenced in the patient
population as described below in the section entitled PCR and
DNA sequencing except that analysis of the IVS2-2A.G variant was
conducted as reported previously [16]. Novel sequence variants
identified in patients in this study were confirmed either by
sequencing in the opposite direction or by RFLP or TaqManH
analysis as described below in the sections entitled RFLP analysis
and TaqManH analysis, except that the g.55275A.G variant was
also confirmed by bidirectional sequencing. Due to the size of the
study population and the SLC26A5 gene, at least one occurrence of
every previously reported variant assayed by sequencing was
confirmed by a second sequencing reaction in the opposite
direction or by TaqManH analysis, however, additional
occurrences were only confirmed when deemed appropriate for
control purposes or necessary based on the appearance of the
initial sequence electropherogram.
Of controls. Screening of the control population for the
sequence variants observed in patients was conducted by
sequencing as described below in the section entitled PCR and
DNA sequencing or, as indicated, by RFLP or TaqManH analysis as
described below in the sections entitled RFLP analysis and
TaqManH analysis. Novel sequence variants identified only in
controls in this study were confirmed either by sequencing in the
opposite direction or by a second confirmatory sequencing
reaction in the same direction as the first. However, due to the
size of the study population and the SLC26A5 gene, previously
reported variants assayed by sequencing were only confirmed by a
second sequencing reaction either in the opposite direction or in
the same direction as the first when deemed necessary for
confirmation based on the appearance of the initial sequence
electropherogram.
PCR and DNA sequencing. To minimize the number of
PCR reactions required to amplify the coding and near coding
genomic sequence of SLC26A5, a combination of standard and
long PCR was used. Standard PCR was conducted with Taq
polymerase (GE Healthcare, Piscataway, NJ, USA). Long PCR
was conducted with the Expand Long Template PCR System
(Roche Applied Science, Indianapolis, IN, USA). PCR reactions
were conducted as follows: initial denaturation at 94uC was
followed by 40 cycles of amplification which included denaturation
at 94uC, annealing at temperatures ranging from 53uCt o6 0 uC
dependent upon primer sequence, and extension at 70uC for
standard PCR and 68uC for long PCR. Amplification was
followed by a final extension at 70uC for standard PCR and
68uC for long PCR.
Amplified fragments were sequenced using either PCR or inset
sequencing primers with fluorescently labeled dideoxynucleotides
by chain terminator (Sanger) methods using the ABI BigDye
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems,
Foster City, CA, USA) as previously described [16]. Sequencing
reactions were analyzed on an ABI Prism 3130 Genetic Analyzer
according to manufacturer’s specifications (Applied Biosystems,
Foster City, CA, USA).
Primer sequences and detailed PCR conditions will be provided
upon request.
RFLP analysis. Restriction digests were performed according
to the restriction enzyme manufacturer’s specifications. PCR
fragments containing position g.33190 were digested with
restriction enzyme BstNI (New England Biolabs, Ipswich, MA,
USA). When the consensus sequence was present, the 350 bp
PCR fragment was not digested. When the T.G variant sequence
was present, the digestion resulted in two fragments of 250 bp and
100 bp.
PCR fragments containing position g.53884 were digested with
restriction enzyme EcoO109I (New England Biolabs, Ipswich,
MA, USA). When the consensus sequence was present, the
digestion resulted in two fragments of 420 bp and 180 bp. When
the C.T variant sequence was present, the 600 bp PCR fragment
was not digested.
PCR fragments containing position g.66012 were digested with
restriction enzyme DraIII (New England Biolabs, Ipswich, MA,
USA). When the consensus sequence was present, the digestion
resulted in two fragments of 225 bp and 140 bp. When the C.T
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TaqManH analysis. TaqManH assays were performed
according to the manufacturer’s recommendations. Premade
TaqManH SNP Genotyping Assays (Applied Biosystems, Foster
City, CA, USA) were used for the detection of sequence variants
g.33167T.C (Assay ID C_25989012_10), g.34821C.T (Assay
ID C_25742018_10) and g.69036T.C (Assay ID
C_25986987_10). Custom TaqManH SNP Genotyping Assays
were designed for analysis of sequence variants g.55275A.G and
g.67439T.C.
In silico DNA analysis. Missense amino acid sequence
variations were analyzed for potential pathogenicity using the
PolyPhen (http://genetics.bwh.harvard.edu/pph/) [20] and SIFT
(http://blocks.fhcrc.org/sift/SIFT.html) [21] sequence analysis
algorithms. Both algorithms use information from multiple
sequence alignments of similar proteins to predict whether an
amino acid substitution at any given position would be tolerated.
PolyPhen also incorporates analysis of structural information into
predictions. Protein sequence P58743 (version P58743.1,
GI:20139418) from the UniProtKB/Swiss-Prot (http://www.ebi.
ac.uk/swissprot/) and NCBI GenPept databases (http://www.
ncbi.nlm.nih.gov) was used as the reference sequence for these
analyses.
Multiple sequence alignments for prestin orthologs from
multiple species were derived using the HomoloGene application
on the National Center for Biotechnology Information (NCBI)
web site (http://www.ncbi.nlm.nih.gov). Species and protein
reference sequences included in the multiple sequence alignment
are shown in Table 5.
dbSNP submission. All novel DNA sequence variants
identified in SLC26A5 in this study were submitted to dbSNP
(http://www.ncbi.nlm.nih.gov) and assigned rs numbers in Build
130 as indicated in Table 1.
Statistical analysis. Two-tailed P values associated with
allele frequencies in patients and controls were calculated using the
Fisher’s exact test analysis of 262 contingency tables algorithm
available through GraphPad QuickCalcs Online Calculator for
Scientists (http://www.graphpad.com/quickcalcs/index.cfm).
Heterozygosity. Heterozygosity (H) is calculated as the
number of heterozygous individuals divided by the total number
of individuals tested.
Haplotype analysis. Haplotype analysis was conducted
using HaploView 4.0 software (http://www.broad.mit.edu/mpg/
haploview) [22]. International HapMap Project data markers
(http://www.hapmap.org) [23] and DNA sequence variations
evaluated in SLC26A5 in this study were uploaded into HaploView
4.0 software for analysis as singletons in Linkage format. Blocks
were defined using the four gamete rule. Haplotypes above 1%
were examined.
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